- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05416697
Effectiveness of Cannabinoids on Appetite in Scleroderma
Effectiveness of Cannabinoid on Appetite, Sleep Quality, Quality of Life, Joint Pain, and Cytokine Level in Systemic Sclerosis Patients: a Randomized Placebo-controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Systemic sclerosis (SSc) is a connective tissue disease for which skin tightness is the hallmark. The disease is classified into 2 major subsets: limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc) depending on the extent of skin tightness. Not only the skin tightness but also the internal organs such as the musculoskeletal, kidneys, lungs, heart, and intestines can be involved and associated with a poor outcome. Malnutrition and/or weight loss is a complications in SSc. The complication is possibly related to gastrointestinal involvement, inflammation, immunosuppressant agents, or mood disturbance which can affect the food appetite or eating behavior. As well as sleep quality, sleep disturbance has been reported in SSc patients and the associated factor of sleep disturbance in those patients was gastrointestinal involvement, particularly gastroesophageal reflux disease, the severity of pain, and depressed mood. The cannabinoid is an agent which affects appetite, pain, and sleep quality as mentioned above, hence it would improve the appetite, get a high sleep quality and reduce pain associated with musculoskeletal involvement in SSc patients.
Although cannabinoid has benefit in many aspects, they also resulted in serious adverse events after cannabinoid inhalation, including ischemic stroke related to vasospasm of the cerebral vessel, high cardiac output, cardiac arrhythmias, blood pressure fluctuation, and respiratory tract infection. Acute toxicity has been reported and depended on unit dose, tolerance, and route of cannabinoid use. Cannabis also influenced brain function including memory, and cognitive function, and expanded the risk for psychosis in those who had prolonged use. The symptoms of central nervous system (CNS) toxicity include euphoria, panic, agitation, mood alterations, alteration of perception, loss of social inhibition, muscle incoordination, myoclonic jerking, ataxia, slurred speech, and risk of the suicidal idea. In addition, prolonged high doses of cannabis use can lead to the development of cannabinoid hyperemesis syndrome caused by cyclic hyperemesis, finally resulting in electrolyte disturbances and impaired kidney function.
Because the evidence of the effect of cannabinoids in humans with SSc is limited. We, therefore, would like to investigate the efficacy of cannabinoids on the appetite, sleep efficiency, quality of life, pain, and key cytokine level in SSc compared with placebo in SScpatientst and the adverse events associated with cannabinoids in those patients.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Chingching Foocharoen, M.D.
- Phone Number: 6643363746
- Email: fching@kku.ac.th
Study Locations
-
-
-
Khon Kaen, Thailand, 40002
- Recruiting
- Department of Medicine, Faculty of Medicine, Khon Kaen University
-
Contact:
- Chingching Foocharoen, MD
- Phone Number: 6643363746
- Email: fching@kku.ac.th
-
Principal Investigator:
- Chingching Foocharoen, MD
-
Khon Kaen, Thailand, 40002
- Recruiting
- Scleroderma Clinic, Faculty of Medicine, Khon Kaen University
-
Contact:
- Chingching Foocharoen, MD
- Phone Number: 6643363746
- Email: fching@kku.ac.th
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- SSc patients aged between 18 and 65 years
- Diagnosed according to ACR/EULAR 2013 classification criteria
- Having anorexia or malnutrition status
- Must not receive steroid equivalent to prednisolone dose more than 10 mg/d
- Must receive a stable dose of steroid, immunosuppressant, and/or vitamin or its supplement within 2 weeks before enrollment
- Must stop anxiolytics, hypnotics, or sleeping pills at least 2 weeks before enrollment
- Understand and able to read and write the Thai language
Exclusion Criteria:
- Overlap with other connective tissue diseases
- Pregnancy or lactation
- Bedridden and confined to no self-care
- Evidence of active malignant disease
- Present uncontrolled or severe medical problems including diabetes mellitus, asthma, angina, cardiovascular, thyroid, hepatic, or renal diseases (Cr>1.4 mg/dl)
- Present active infection that needs systemic antibiotic
- Previous allergy to cannabinoid or their derivatives
- Concomitant illegal drug used (amphetamine or its derivative, cocaine)
- History of the previous cannabinoid using or concomitant any herbal included cannabinoid used
- On-going anxiolytics, hypnotics, or sleeping pills used
- In a period that needs immunosuppressant dose adjustment
- Having active SSc that needs closed monitoring for disease progression (pulmonary hypertension, proteinuria, microscopic hematuria, digital gangrene, and progressive interstitial lung disease)
- Having unstable cardiopulmonary disease (angina, peripheral vascular disease, cerebrovascular disease, and arrhythmia) and risk of cardiovascular disease
- Having a history of schizophrenia, concurrent active mood disorder, or anxiety disorders
- Receiving the following medications that cause drug interaction with cannabinoids: fluoroquinolone, rifampicin, fluoxetine, warfarin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: cannabinoid
Cannabinoid in form of cannabis 2.7 mg THC 2.5 mg twice daily (1 droplet twice daily; 0.73 mg THC and 0.81 mg CBD/drop, 1.46 mg THC and 1.62 CBD/day) for 1 week then titrate up to 2 droplets twice daily if tolerated (2.92 mg THC and 3.24 CBD per day) and continue the treatment until the end of the study
|
The subjects will receive cannabis 2.7 mg THC 2.5 mg CBD twice daily (1 droplet twice daily; 0.73 mg THC and 0.81 mg CBD/drop, 1.46 mg THC and 1.62 CBD/day) for 1 week then titrate up to 2 droplets twice daily if tolerated (2.92 mg THC and 3.24 CBD per day) and continue the treatment until the end of the study.
|
Placebo Comparator: placeba
Placebo 1 droplet twice daily for 1 week then titrate up to 2 droplets twice daily if tolerated and continue the treatment until the end of the study
|
The subjects will receive 1 droplet of placebo twice daily then titrate up to 2 droplets twice daily if tolerated and continue the treatment until the end of the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The changing of appetite
Time Frame: 4 weeks
|
50% increase of appetite evaluated by a visual analogue scale (VAS) from 0-100* compared to baseline and a comparison between the treatment group and placebo group *a higher score, a more appetite |
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The changing of serum transferrin level
Time Frame: 4 weeks
|
The mean difference of serum transferrin level compare to baseline and a comparison between the treatment group and placebo group
|
4 weeks
|
An adverse event
Time Frame: 4 weeks
|
An adverse event
|
4 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The changing of sleep quality
Time Frame: 4 weeks
|
The changing of sleep quality evaluated by the Thai Pittsburgh Sleep Quality Index* compare to baseline and a comparison between the treatment group and placebo group *the score ranges from 0-to 21 and the higher score, the poorer sleep quality |
4 weeks
|
The changing of quality of life
Time Frame: 4 weeks
|
The changing of the quality of life evaluated by EuroQol group 5 dimensions (EQ-5D)* compare to baseline and a comparison between the treatment group and placebo group *the index composes of 5 dimensions and each dimension includes 3 levels (no problems, some problems, and extreme problems), the higher level of the dimension, the poorer quality of life |
4 weeks
|
The changing pain symptoms
Time Frame: 4 weeks
|
50% decrease of joint pain evaluated by VAS from 0-100* compare to baseline and a comparison between the treatment group and placebo group *a higher scale, a more pain |
4 weeks
|
The changing of cytokine level (transforming growth factor beta)
Time Frame: 4 weeks
|
The changing of cytokine level compare to baseline and a comparison between the treatment group and placebo group
|
4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chingching Foocharoen, M.D., Khon Kaen University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Cannabinoid in scleroderma
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malnutrition
-
HAN University of Applied SciencesFrieslandCampina; HAS Hogeschool; Centre of Expertise Food (CoE Food); SligroCompletedMalnutrition; Protein | Protein MalnutritionNetherlands
-
International Centre for Diarrhoeal Disease Research...GlaxoSmithKline; Stanford UniversityCompletedMalnutrition | Malnutrition in Children | Child MalnutritionBangladesh
-
University of Nove de JulhoUnknownMalnutrition, ChildBrazil
-
International Centre for Diarrhoeal Disease Research...UNICEFNot yet recruitingMalnutrition SevereBangladesh
-
UNICEFSave the ChildrenCompletedSevere MalnutritionCongo, The Democratic Republic of the
-
University of Erlangen-Nürnberg Medical SchoolPfrimmer Nutricia GmbH, Erlangen , GermanyCompletedNursing Home Residents | Malnutrition or Risk of MalnutritionGermany
-
Aga Khan UniversityAction Contre la FaimCompletedEvaluation of the Effectiveness and Impact of Community Case Management of Severe Acute MalnutritionSevere MalnutritionPakistan
-
Action Against Hunger USAUniversity of Washington; Ethiopian Public Health InstituteNot yet recruitingModerate Acute Malnutrition | Severe Acute Malnutrition
-
Academy of Nutrition and DieteticsHartford Hospital; University of New Mexico; Meals on Wheels Central TexasNot yet recruiting
-
Diego MorettiSwiss Federal Institute of Technology; Wageningen University and Research; St... and other collaboratorsCompletedMalnutrition; ProteinSwitzerland
Clinical Trials on CBD oil
-
University of Texas at AustinWay West Wellness; SunFlora.IncSuspendedAnger | Sleep Disturbance | Anxiety Depression | Substance Abuse | Alcohol Abuse | Stress ReactionUnited States
-
Hartford HospitalYale UniversityActive, not recruiting
-
University of Texas at AustinSuspendedPost Traumatic Stress DisorderUnited States
-
Gold Coast Hospital and Health ServiceBod AustraliaActive, not recruitingMotor Neuron Disease | Amyotrophic Lateral SclerosisAustralia
-
Weill Medical College of Cornell UniversityNutra PureCompletedTMD | TMJ Disorder | Myofacial PainUnited States
-
Canopy Growth CorporationCentre for Addiction and Mental Health; McMaster UniversityWithdrawn
-
University Health Network, TorontoRecruitingChronic Pain | Cannabis | Opioid UseCanada
-
University of OklahomaNot yet recruitingForehead; Wound
-
Eastern Virginia Medical SchoolOld Dominion University; Ananda Hemp, Inc.RecruitingDementia | Alzheimer Disease | Major Neurocognitive Disorder With Aggressive BehaviorUnited States
-
University of FloridaConsortium for Medical Marijuana Clinical Outcomes ResearchCompletedChronic InflammationUnited States